EnerSpar Corp. (TSE:NRX) has released an update.
NurExone Biologic Inc., a biopharmaceutical company specializing in treatments for spinal cord injuries, has announced its shares are now trading on the OTCQB Venture Market and have achieved DTC eligibility, aiming to increase visibility, investor access, and liquidity for U.S. investors. This move is part of the company’s strategy to expand its investor base and accelerate the development of its innovative exosome-based therapies. NurExone continues to trade on the TSX Venture Exchange and several German stock exchanges while working on solutions for Central Nervous System injuries.
For further insights into TSE:NRX stock, check out TipRanks’ Stock Analysis page.
